Baird analyst Brian Skorney downgraded Applied Therapeutics (APLT) to Neutral from Outperform with a price target of 25c, down from $2, after Applied agreed to be acquired by Cycle Group for 8.8c per share in cash payable at closing plus one non-transferrable contingent value right that entitles the holder to receive potential additional payments.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLT: